Дэниел Левитин - Счастливое старение. Рекомендации нейробиолога о том, как жить долго и хорошо

J. A. Gandelman, P. Newhouse, and W. D. Taylor, “Nicotine and Networks: Potential for Enhancement of Mood and Cognition in Late-Life Depression,” Neuroscience and Biobehavioral Reviews 84 (2018): 289–298.

G. E. Barreto, A. Iarkov, and V. E. Moran, “Beneficial Effects of Nicotine, Cotinine and Its Metabolites as Potential Agents for Parkinson’s Disease,” Frontiers in Aging Neuroscience 6 (2015): 340; M. Kolahdouzan and M. J. Hamadeh, “The Neuroprotective Effects of Caffeine in Neurodegenerative Diseases,” CNS Neuroscience and Therapeutics 23, no. 4 (2017): 272–290.

D. Hurley, “Will a Nicotine Patch Make You Smarter?” Scientific American, February 9, 2014, https://www.scientificamerican.com/article/will-a-nicotine-patch-make-you-smarter-excerpt/.

J. A. Apud et al., “Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects,” Neuropsychopharmacology 32, no. 5 (2007): 1011.

N. Borges, “Tolcapone-Related Liver Dysfunction,” Drug Safety 26, no. 11 (2003): 743–747.

J. Micallef et al., “Antiparkinsonian Drug-Induced Sleepiness: A Double-Blind Placebo-Controlled Study of L-Dopa, Bromocriptine and Pramipexole in Healthy Subjects,” British Journal of Clinical Pharmacology 67, no. 3 (2009): 333–340; D. A. Pizzagalli et al., “Single Dose of a Dopamine Agonist Impairs Reinforcement Learning in Humans: Behavioral Evidence from a Laboratory-Based Measure of Reward Responsiveness,” Psychopharmacology 196, no. 2 (2008): 221–232.

Из личного общения с Дэйвом Гамильтоном 8 июня 2019 года.

A. Ströhle et al., “Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials,” American Journal of Geriatric Psychiatry 23, no. 12 (2015): 1234–1249; J. T. O’Brien et al., “Clinical Practice with Anti-Dementia Drugs: A Revised (Third) Consensus Statement from the British Association for Psychopharmacology,” Journal of Psychopharmacology 31, no. 2 (2017): 147–168.

B. M. Altevogt, M. Davis, and D. E. Pankevich, eds., Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary (Washington, DC: National Academies Press, 2011).

Из личного общения с Карлосом Квинтаной 21 мая 2018 года.

P. L. Santaguida, T. A. Shamliyan, and D. R. Goldmann, “Cholinesterase Inhibitors and Memantine in Adults with Alzheimer Disease,” American Journal of Medicine 129, no. 10 (2016): 1044–1047.

C. M. Gameiro, F. Romão, and C. Castelo-Branco, “Menopause and Aging: Changes in the Immune System – A Review,” Maturitas 67, no. 4 (2010): 316–320; C. Castelo-Branco and I. Soveral, “The Immune System and Aging: A Review,” Gynecological Endocrinology 30, no. 1 (2014): 16–22.

A. Spector et al., “Efficacy of an Evidence-Based Cognitive Stimulation Therapy Programme for People with Dementia: Randomised Controlled Trial,” British Journal of Psychiatry 183, no. 3 (2003): 248–254; J. D. Huntley et al., “Do Cognitive Interventions Improve General Cognition in Dementia? A Meta-Analysis and Meta-Regression,” BMJ Open 5, no. 4 (2015): e005247.

J. Birks and J. G. Evans, “Ginkgo Biloba for Cognitive Impairment and Dementia,” Cochrane Database of Systematic Reviews 1 (2009); J. Geng et al., “Ginseng for Cognition,” Cochrane Database of Systematic Reviews 12 (2010); P. E. Gold, L. Cahill, and G. L. Wenk, “Ginkgo Biloba: A Cognitive Enhancer?” Psychological Science in the Public Interest 3, no. 1 (2002): 2–11; A. W. Rutjes et al., “Vitamin and Mineral Supplementation for Maintaining Cognitive Function in Cognitively Healthy People in Mid and Late Life,” Cochrane Database of Systematic Reviews 12 (2018); Q. Yuan et al., “Effects of Ginkgo Biloba on Dementia: An Overview of Systematic Reviews,” Journal of Ethnopharmacology 195 (2017): 1–9.

NIH Office of Dietary Supplements, “Vitamin B12,” November 29, 2018, https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/.

G. Scalabrino, “The Multi-Faceted Basis of Vitamin B12 (Cobalamin) Neurotrophism in Adult Central Nervous System: Lessons Learned from Its Deficiency,” Progress in Neurobiology 88, no. 3 (2009): 203–220.

D. Kennedy, “B Vitamins and the Brain: Mechanisms, Dose and Efficacy– A Review,” Nutrients 8, no. 2 (2016): 68.

J. L. Reay, M. A. Smith, and L. M. Riby, “B Vitamins and Cognitive Performance in Older Adults,” ISRN Nutrition 2013 (2013).

R. Malouf and A. A. Sastre, “Vitamin B12 for Cognition,” Cochrane Database of Systematic Reviews 3 (2003).

D. M. Zhang et al., “Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients with Cognitive Related Diseases: A Systematic Review and Meta-Analysis,” Journal of Geriatric Psychiatry and Neurology 30, no. 1 (2017): 50–59.

R. L. Kane et al., “Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia,” Comparative Effectiveness Reviews 188 (2017).

G. Douaud et al., “Preventing Alzheimer’s Disease-Related Gray Matter Atrophy by B-Vitamin Treatment,” Proceedings of the National Academy of Sciences 110, no. 23 (2013): 9523–9528.

B. Bistrian, “Should I Stop Taking These Vitamins?” Harvard Health Letter, May 2010.

PrimalHerb, https://primalherb.com/product/neuro-shroom/?rfsn=2393934.d10479. Я уже писал об этом в статье: D. J. Levitin, “What It Was Like Doing Mushrooms with Grateful Dead’s Bob Weir,” High Times, March 22, 2019.

E. Ulziijargal and J. L. Mau, “Nutrient Compositions of Culinary-Medicinal Mushroom Fruiting Bodies and Mycelia,” International Journal of Medicinal Mushrooms 13, no. 4 (2011).

K. Mori et al., “Effects of Hericium erinaceus on Amyloid β (25–35) Peptide-Induced Learning and Memory Deficits in Mice,” Biomedical Research 32, no. 1 (2011): 67–72.

K. Mori et al., “Improving Effects of the Mushroom Yamabushitake (Hericium erinaceus) on Mild Cognitive Impairment: A Double-Blind Placebo-Controlled Clinical Trial,” Phytotherapy Research 23, no. 3 (2009): 367–372.

M. Nagano et al., “Reduction of Depression and Anxiety by 4 Weeks Hericium erinaceus Intake,” Biomedical Research 31, no. 4 (2010): 231–237.

H. Zhao et al., “Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial,” Evidence-Based Complementary and Alternative Medicine 2012 (2012).

Y. Zhou et al., “Neuroprotective Effect of Preadministration with Ganoderma lucidum Spore on Rat Hippocampus,” Experimental and Toxicologic Pathology 64, nos. 7–8 (2012): 673–680.

S. Huang et al., “Polysaccharides from Ganoderma lucidum Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer’s Disease,” Stem Cell Reports 8, no. 1 (2017): 84–94.

W. B. Stavinoha, “Status of Ganoderma lucidum in United States: Ganoderma lucidum as an Anti-Inflammatory Agent,” in Proceedings of the 1st International Symposium on Ganoderma Lucidum in Japan, pp. 17–18 (2008).

W. J. Li et al., “Ganoderma atrum Polysaccharide Attenuates Oxidative Stress Induced by D-Galactose in Mouse Brain,” Life Sciences 88, nos. 15–16 (2011): 713–718.

L. Feng et al., “The Association between Mushroom Consumption and Mild Cognitive Impairment: A Community-Based Cross-Sectional Study in Singapore,” Journal of Alzheimer’s Disease 68 (2019): 197–203.

S. C. Pierce et al., “Hydrology and Species-Specific Effects of Bacopa monnieri and Leersia oryzoides on Soil and Water Chemistry,” Ecohydrology: Ecosystems, Land and Water Process Interactions, Ecohydrogeomorphology 2, no. 3 (2009): 279–286.

C. Stough et al., “The Chronic Effects of an Extract of Bacopa monniera (Brahmi) on Cognitive Function in Healthy Human Subjects,” Psychopharmacology 156, no. 4 (2001): 481–484.

S. Roodenrys et al., “Chronic Effects of Brahmi (Bacopa monnieri) on Human Memory,” Neuropsychopharmacology 27, no. 2 (2002): 279.

P. D. Charles et al., “Bacopa monniera Leaf Extract Up-Regulates Tryptophan Hydroxylase (TPH2) and Serotonin Transporter (SERT) Expression: Implications in Memory Formation,” Journal of Ethnopharmacology 134, no. 1 (2011): 55–61.

L. Mlodinow, Elastic: Flexible Thinking in a Time of Change (New York: Pantheon, 2018). ( Млодинов Л. Эластичность. Гибкое мышление в эпоху перемен. М.: Livebook, 2020.)

Hopkins Medicine Staff, “Single Dose of Hallucinogen May Create Lasting Personality Change,” September 29, 2011, https://www.hopkinsmedicine.org/news/media/releases/single_dose_of_hallucinogen_may_create_lasting_personality_change.

J. Zack, “Michael Pollan Takes a Trip in His Latest Book, ‘How to Change Your Mind,’ ” San Francisco Chronicle, May 21, 2018, https://www.sfchronicle.com/books/article/Michael-Pollan-gets-stoned-in-his-latest-book-12932010.php.

D. Nutt, Drugs without the Hot Air: Minimising the Harms of Legal and Illegal Drugs (Cambridge: UIT Cambridge, 2012), p. 254.

S. Belli, “A Psychobiographical Analysis of Brian Douglas Wilson: Creativity, Drugs, and Models of Schizophrenic and Affective Disorders,” Personality and Individual Differences 46, no. 8 (2009): 809–819. См. также: D. H. Linszen, P. M. Dingemans, and M. E. Lenior, “Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders,” Archives of General Psychiatry 51, no. 4 (1994): 273–279

J. Saliba et al., “Functional Near-Infrared Spectroscopy for Neuroimaging in Cochlear Implant Recipients,” Hearing Research 338 (2016): 64–75.

A. P. Sanderson et al., “Exploiting Routine Clinical Measures to Inform Strategies for Better Hearing Performance in Cochlear Implant Users,” Frontiers in Neuroscience 12 (2019).

J. M. Bronstein et al., “Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues,” Archives of Neurology 68, no. 2 (2011): 165.